FIA
SPPI

FNY Investment Advisers’s Spectrum Pharmaceuticals Inc SPPI Stock Holding History

FNY Investment Advisers’s Portfolio SPPI Stock Details SPPI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,500
Closed -$31K – 1377
2018
Q2 		$31K Buy
+1,500
New +$27.8K 0.01% 324

Other funds holding SPPI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

FNY Investment Advisers's SPPI Position: Q3 2018 in Review

FNY Investment Advisers sold out of Spectrum Pharmaceuticals Inc (SPPI) in Q3 2018, closing a stake of 1,500 shares — an estimated $31K sold.

FNY Investment Advisers first reported a position in SPPI in Q2 2018 and held it in 1 quarter. The position peaked at $31K in Q2 2018. 190 funds tracked by Wall St. Rank hold SPPI as of Q3 2018.

  • FNY Investment Advisers reported no remaining Spectrum Pharmaceuticals Inc position as of Q3 2018 after selling out during the quarter.
  • FNY Investment Advisers sold 1,500 Spectrum Pharmaceuticals Inc shares in Q3 2018, an estimated $31K.
  • FNY Investment Advisers first reported a position in Spectrum Pharmaceuticals Inc in Q2 2018 and held it in 1 quarter.
  • FNY Investment Advisers's Spectrum Pharmaceuticals Inc position peaked at $31K in Q2 2018.
  • 190 funds tracked by Wall St. Rank held Spectrum Pharmaceuticals Inc as of Q3 2018.

Based on FNY Investment Advisers's 13F filing for Q3 2018, filed 29 Oct 2018.